Hainan Huluwa Pharmaceutical Group Co Ltd (605199) - Total Assets

Latest as of March 2026: CN¥2.56 Billion CNY ≈ $374.03 Million USD

Based on the latest financial reports, Hainan Huluwa Pharmaceutical Group Co Ltd (605199) holds total assets worth CN¥2.56 Billion CNY (≈ $374.03 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Hainan Huluwa Pharmaceutical Group Co Lt to assess the company's total reinvestment commitment from operating cash flow.

Hainan Huluwa Pharmaceutical Group Co Ltd - Total Assets Trend (2016–2025)

This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data. Check Hainan Huluwa Pharmaceutical Group Co Lt earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Hainan Huluwa Pharmaceutical Group Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Hainan Huluwa Pharmaceutical Group Co Ltd's total assets of CN¥2.56 Billion consist of 33.9% current assets and 66.1% non-current assets.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	3.0%
Accounts Receivable	CN¥418.01 Million	16.1%
Inventory	CN¥254.34 Million	9.8%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥274.49 Million	10.6%
Goodwill	CN¥0.00	0.0%

Asset Composition Trend (2016–2025)

This chart illustrates how Hainan Huluwa Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 605199 market cap overview.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Hainan Huluwa Pharmaceutical Group Co Ltd's current assets represent 33.9% of total assets in 2025, a decrease from 41.1% in 2016.
Cash Position: Cash and equivalents constituted 3.0% of total assets in 2025, down from 11.6% in 2016.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 20.0% in 2016.
Asset Diversification: The largest asset category is accounts receivable at 16.1% of total assets.

Hainan Huluwa Pharmaceutical Group Co Ltd Competitors by Total Assets

Key competitors of Hainan Huluwa Pharmaceutical Group Co Ltd based on total assets are shown below.

Company	Country	Total Assets
Tonghua Dongbao Pharmaceutical Co Ltd SHG:600867	China	CN¥8.25 Billion
Eris Lifesciences Limited NSE:ERIS	India	Rs71.60 Billion
Zhejiang Hisun Pharmaceutical Co Ltd SHG:600267	China	CN¥13.81 Billion
Lotus Pharmaceutical Co Ltd TW:1795	Taiwan	NT$106.15 Billion
Tasly Pharmaceutical Group Co Ltd SHG:600535	China	CN¥15.69 Billion
Changzhou Qianhong Biopharma Co Ltd SHE:002550	China	CN¥3.23 Billion
Renhe Pharmacy Co Ltd SHE:000650	China	CN¥7.93 Billion
Sun Pharma Advanced Research Company Limited NSE:SPARC	India	Rs3.22 Billion

Hainan Huluwa Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	0.63	0.84	2.22
Quick Ratio	0.46	0.53	1.69
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥-510.46 Million	CN¥-232.47 Million	CN¥434.27 Million

Hainan Huluwa Pharmaceutical Group Co Ltd - Advanced Valuation Insights

This section examines the relationship between Hainan Huluwa Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	6.97
Latest Market Cap to Assets Ratio	0.14
Asset Growth Rate (YoY)	-12.2%
Total Assets	CN¥2.60 Billion
Market Capitalization	$356.56 Million USD

Valuation Analysis

Below Book Valuation: The market values Hainan Huluwa Pharmaceutical Group Co Ltd's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Hainan Huluwa Pharmaceutical Group Co Ltd's assets decreased by 12.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Hainan Huluwa Pharmaceutical Group Co Ltd (2016–2025)

The table below shows the annual total assets of Hainan Huluwa Pharmaceutical Group Co Ltd from 2016 to 2025.

Year	Total Assets	Change
2025-12-31	CN¥2.60 Billion ≈ $380.89 Million	-12.20%
2024-12-31	CN¥2.96 Billion ≈ $433.81 Million	-3.14%
2023-12-31	CN¥3.06 Billion ≈ $447.85 Million	+32.37%
2022-12-31	CN¥2.31 Billion ≈ $338.33 Million	+31.30%
2021-12-31	CN¥1.76 Billion ≈ $257.68 Million	+15.76%
2020-12-31	CN¥1.52 Billion ≈ $222.59 Million	+39.99%
2019-12-31	CN¥1.09 Billion ≈ $159.00 Million	-0.49%
2018-12-31	CN¥1.09 Billion ≈ $159.79 Million	+35.28%
2017-12-31	CN¥807.21 Million ≈ $118.12 Million	+50.61%
2016-12-31	CN¥535.95 Million ≈ $78.43 Million	--

About Hainan Huluwa Pharmaceutical Group Co Ltd

SHG:605199 China Drug Manufacturers - Specialty & Generic

Market Cap

$356.56 Million

CN¥2.44 Billion CNY

Market Cap Rank

#14087 Global

#4212 in China

Share Price

CN¥6.09

Change (1 day)

-0.65%

52-Week Range

CN¥6.09 - CN¥10.20

All Time High

CN¥48.21